Current Report Filing (8-k)
June 14 2023 - 4:26PM
Edgar (US Regulatory)
0001279704
false
0001279704
2023-06-14
2023-06-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
June 14, 2023
Cellectar
Biosciences, Inc.
(Exact name of Registrant as Specified in its
Charter)
Delaware | |
1-36598 | |
04-3321804 |
(State or other jurisdiction
of incorporation) | |
(Commission
File Number) | |
(IRS Employer
Identification No.) |
100
Campus Drive, Florham Park, NJ, 07932
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including
area code: (608) 441-8120
N/A
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange
on which registered |
Common
Stock, par value $0.00001 per share |
|
CLRB |
|
The
Nasdaq
Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
The Adjourned
Cellectar Annual Meeting of Stockholders Reconvenes Friday, June 23, 2023
On June 14, 2023, Cellectar Biosciences, Inc., (the “Company”)
convened and then determined to adjourn its 2023 Annual General Meeting of Stockholders (the “Annual Meeting”), because the
Company did not have a sufficient number of shares of the Company’s common stock present in person or represented by proxy at the
Annual Meeting to have constituted a quorum. The adjourned meeting will reconvene on Friday, June 23, 2023 at 10:00 A.M., local time,
at the Company’s headquarters at 100 Campus Drive, Florham Park, New Jersey 07932.
The close of business on April 25, 2023 will continue to be the record
date for the determination of stockholders of the Company entitled to vote at the Annual Meeting. Stockholders of the Company who have
previously submitted their proxy or otherwise voted and who do not want to change their vote do not need to take any action.
No changes have been made in the proposals to be voted on by stockholders
at the Annual Meeting. The Company encourages all of its stockholders to read the Company’s definitive proxy statement on Schedule
14A, filed with the Securities and Exchange Commission (the “SEC”) on April 28, 2023 (the “Proxy Statement”),
which is available on the SEC’s website at www.sec.gov, on the Company’s website at https://investor.cellectar.com/sec-filings
and on the voting platform at www.proxyvote.com.
The Company will continue to solicit votes from its stockholders with
respect to the proposals set forth in the Proxy Statement. The Company encourages all stockholders who have not yet voted to do so before
Thursday, June 22, 2023 at 11:59 p.m., Eastern Time.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CELLECTAR BIOSCIENCES, INC. |
|
|
|
Date: June 14, 2023 |
By: |
/s/ Chad J. Kolean |
|
Name: |
Chad J. Kolean |
|
Title: |
Chief Financial Officer |
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Jul 2023 to Jul 2024